

Scott & White Hospital & Clinics Clinical Research at Scott & White

Please complete this form for each of your studies that are currently enrolling subjects. This information will be used to create a web page available for viewing by the general public. Please use lay terminology as in the consent form. The information should be complete and accurately describe your studies.

Study Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Sitaxsentan Sodium in Subjects with Pulmonary Arterial Hypertension (Protocol #B1321001)

Project ID#: 81461

Department: Pulmonary

Sponsor: Pfizer

1. Provide a brief synopsis of the study (purpose of the study from abstract, consent form, or protocol using lay terminology):

Condition(s):	Treatment(s):
Pulmonary Arterial Hypertension	sitaxsentan sodium 100mg versus placebo (control)

You are being asked to participate in this study because you have been diagnosed with pulmonary arterial hypertension (PAH). PAH is a medical condition defined by an increase in blood pressure in the pulmonary artery. The pulmonary artery is the blood vessel that carries blood from the right side of your heart to the lungs. This research study will evaluate sitaxsentan sodium (called sitaxsentan from now on) for the treatment of PAH. Sitaxsentan is one of a group of drugs called endothelin receptor antagonists (ERAs) that work to improve blood flow to the lungs. This medication has not been approved by the U.S. Food and Drug Administration (FDA) for use and is considered experimental.

The purpose of this research study is to evaluate the safety and effectiveness of sitaxsentan compared to placebo for the treatment of subjects with PAH. This study will measure the distance you can walk in 6 minutes to determine the effect of the study drug. This study will also assess your PAH symptoms for any new or worsening side effects due to the study drug.

If you choose to participate in this research study (referred to as the main study), you may also qualify for two extension studies: the open-label study (B1321002) and the combination study (B1321003).

Combination Extension Study (B1321003)

The combination study will investigate the safety and effectiveness of sitaxsentan treatment alone and in combination with another known PAH treatment. Participation in the combo study will last at least 48 weeks and will involve a minimum of 7 clinic visits and safety lab visits every 4 weeks. In order to be considered eligible to participate in the combination study, you must complete the main study and meet a few additional study required criteria.

Open-Label Extension Study (B1321002)

The open-label study will look at the long-term safety of sitaxsentan treatment alone and in combination with a known PAH treatment. Participation in the open-label study will involve clinic visits every 12 weeks and safety lab visits every 4 weeks. You will continue to receive study drug treatment until sitaxsentan is approved by the FDA and is commercially available in your area. In order to be considered eligible to participate in the open-label study, you must meet the criteria described below in addition to the entry criteria that are required for this particular study:

- You have participated in the main study for at least 4 weeks and have discontinued early due to worsening PAH symptoms
- You have discontinued early from the combo study due to worsening PAH symptoms
- You have completed the combo study

2. Who is eligible to participate in the study (basic qualifications such as age, gender, etc.)?

Age: 18 - 80 years old

Gender: Men and Women

- You must weigh at least 40 kg (88 pounds).
- You must have a current diagnosis of PAH.
- You must be able to perform a 6-minute walk test and walk a distance of at least 150 meters (approximately 500 feet).

Patients **cannot** participate in this study if the following apply:

- You have previously used an endothelin receptor antagonist (ERA) such as sitaxsentan, bosentan (Tracleer™), or ambrisentan (Letairis™).
- You have been treated for your PAH within the past 30 days with any of the following: prostacyclin or prostacyclin analogue, phosphodiesterase-5 (PDE-5) inhibitor, intravenous inotropes, and inhaled nitric oxide.
- You have uncontrolled hypertension.
- You have any of the following diseases: chronic liver disease (hepatitis B and/or hepatitis C), kidney and/or liver dysfunction, and heart disease.
- You have obstructive sleep apnea
- You have a history of cancer within the last 5 years.
- You are a female of child-bearing potential and are unwilling to use medically accepted methods of birth control throughout the study; you are pregnant or breastfeeding.
- You have a recent history of alcohol and illegal drug abuse.
- You have a known allergy to the study drugs.
- You have participated in a clinical study involving another investigational drug or device within 30 days prior to the first day of screening.

**** In order to be eligible to participate, you must meet other entry criteria as required by the study protocol and indicated by the study doctor.**

3. What may be involved/required for subject participation (visits, tests, and/or logs, etc.)?

If you agree to take part in this study, your participation will last for 12 weeks, during which time you will be required to visit the clinic at least 5 times. You will also be required to have blood taken every 4 weeks for laboratory tests.

The following tests and procedures will be performed during a three week screening period to determine if you are eligible to participate in this research study:

- Physical examination
- Medical history including medications
- Electrocardiogram (EKG) – a test that measures the electrical activity of your heart
- 6-minute walk test
- Routine blood tests
- Serum pregnancy test

The following tests and procedures may need to be performed if they have not already been completed as part of your routine medical care:

- Echocardiogram - a test that produces an image of the heart using sound waves
- Right heart catheterization - a procedure that measures the amount of blood the heart pumps
- Lung scan - imaging test that shows how your lungs are functioning
- Pulmonary function tests - breathing tests that measure lung function

If you are qualified for the study following these tests, you will be asked to return to the clinic for the Baseline/Randomization visit.

Baseline Visit

The following tests and procedures will be performed:

- Physical examination
- Medical history including medications
- Weight, height, and vital signs
- 6-minute walk test
- Blood draws for routine blood tests and pharmacokinetic (PK) analysis (measures the amount of study drug in your blood)
- Additional blood sample for optional genetic (DNA) testing (****You do not have to donate this blood sample in order to participate in this research study**)
- Serum and urine pregnancy test

At this visit, you will be randomly assigned (like the flip of a coin) to one of the two treatment groups:

- sitaxsentan
- placebo

Placebo is a pill that looks like sitaxsentan except that it contains no active substance and provides no medical benefit. Sitaxsentan and placebo will be supplied by Pfizer (the Sponsor).

You will not know which treatment group you have been assigned to until your participation in the study is complete.

After randomization, you will return to the clinic (as described below) to see your study doctor and have blood drawn.

Clinic Visits

You will come to your study doctor's office for clinic visits at Weeks 4, 8, and 12. The following tests and procedures will be performed at each visit:

- Physical examination
 - Weight and vital signs
 - 6-minute walk test
 - Blood draws for routine blood tests and pharmacokinetic (PK) analysis
 - Serum pregnancy test
 - You will be asked about your medications (including study drug), general health, and PAH symptoms
-

4. Contact Information:

Coordinator(s): Craig Cernosek

Title(s): Clinical Research Coordinator

Telephone Number(s) (no pager numbers): 4-7168

E-mail Address(es): ccernosek@swmail.sw.org
